Peppermint For Indigestion Clinical Trial 2027

Updated for 2025–2026 evidence | Estimated reading time: 14 minutes

---

Table of Contents

1. What This Article Covers
2. Understanding Functional Dyspepsia: Why It Matters
3. The Science Behind Peppermint and Indigestion
4. Key Clinical Trials: What the Numbers Say
5. The 2025/2026 Menthacarin Phase IV Trial
6. Peppermint Oil Alone vs. Peppermint–Caraway Combination
7. Peppermint Tea, Leaves, and Extract: Are They Studied?
8. Dosage and Formulation Used in Clinical Trials
9. Side Effects, Safety, and Drug Interactions
10. How Strong Is the Evidence Compared to PPIs?
11. Is There a 2027 Clinical Trial Coming?
12. Frequently Asked Questions
13. Bottom Line

---

What This Article Covers

If you searched "peppermint for indigestion clinical trial 2027," you are likely asking one of two things: either you want to know what the most current clinical evidence says about using peppermint for indigestion, or you are actively looking for an ongoing or upcoming 2027 trial you might participate in or follow.

This article answers both questions directly.

We will walk you through every major randomized controlled trial (RCT) published on this topic, explain the difference between what has been studied (peppermint–caraway oil combinations) and what has not been well studied (peppermint oil alone, peppermint tea, peppermint extract), report the most recent clinical data from a 2025/2026 phase IV trial, and explain honestly what the current state of research does and does not prove.

By the end, you will know exactly which formulations have clinical backing, what doses were used, what side effects appeared, and what to realistically expect from peppermint as a treatment for indigestion in 2027 and beyond.

Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement, especially if you are pregnant, nursing, taking prescription medications, or managing a diagnosed gastrointestinal condition.

---

Understanding Functional Dyspepsia: Why It Matters

Before diving into clinical trial data, it is important to clarify the medical terminology. When clinical researchers study "indigestion," they typically use the more precise term functional dyspepsia (FD).

Functional dyspepsia is a common gastrointestinal disorder characterized by:

• Epigastric pain or burning (pain in the upper-middle abdomen)
• Postprandial fullness (feeling uncomfortably full after eating a normal-sized meal)
• Early satiation (feeling full after just a few bites)
• Bloating, nausea, or belching

The word "functional" is critical: it means no structural or biochemical cause is found on standard investigations like endoscopy or bloodwork. The symptoms are real and often debilitating, but the mechanism is rooted in gut–brain interaction abnormalities, altered motility, visceral hypersensitivity, or post-infectious changes.

Functional dyspepsia affects an estimated 10–30% of the global population, making it one of the most common and least well-treated GI conditions. Standard pharmaceutical options — proton-pump inhibitors (PPIs), H2-receptor antagonists, prokinetics — work for some patients but not all, carry their own side effect profiles, and are not appropriate for long-term use in every case.

This is precisely why natural peppermint indigestion remedies have attracted significant scientific interest. Peppermint has been used for digestive complaints for centuries, but only in the past two to three decades have researchers begun subjecting it to rigorous clinical trial methodology.

---

The Science Behind Peppermint and Indigestion

How Peppermint Works on the Gut

The primary active compound in peppermint oil is L-menthol, which constitutes roughly 35–55% of the essential oil by weight. Secondary components include menthone, menthyl acetate, menthofuran, and 1,8-cineole.

The proposed mechanisms by which peppermint may address peppermint indigestion symptoms include:

1. Calcium channel antagonism: L-menthol acts as a calcium channel blocker in smooth muscle cells of the gastrointestinal tract, reducing smooth muscle spasm. This is thought to relieve cramping, bloating, and the sensation of excessive gut pressure.

1. Kappa-opioid receptor activation: Some research suggests menthol activates kappa-opioid receptors in the gut, which may reduce visceral pain signaling — a key driver of epigastric pain in functional dyspepsia.

1. TRPM8 receptor activation: Menthol activates the transient receptor potential melastatin 8 (TRPM8) channel, which is involved in cold sensation and is expressed in GI tissue. This pathway may modulate pain perception.

1. Acceleration of gastric emptying: Some evidence suggests peppermint–caraway oil combinations may improve gastric motility, reducing the postprandial fullness that characterizes functional dyspepsia.

1. Antimicrobial and anti-inflammatory effects: Peppermint has demonstrated antimicrobial activity in vitro, and some researchers have hypothesized an anti-inflammatory component to its benefits, though this has not been the primary finding in indigestion-specific trials.

Why Caraway Oil Is Often Combined With Peppermint

Caraway oil (derived from Carum carvi) contains the active compounds carvone and limonene. In combination with peppermint oil, it appears to produce a complementary effect on gut motility and visceral sensitivity. The specific formulation called Menthacarin (also known as STW 5-II or by the brand name Enteroplant in some markets) standardizes this combination at a fixed ratio.

The rationale for the combination: peppermint oil's spasmolytic effects combined with caraway oil's carminative (gas-dispersing) and motility-modulating properties may address the multi-faceted symptom profile of functional dyspepsia more effectively than either component alone.

This distinction becomes extremely important when evaluating the evidence, as we will see in the clinical trial section below.

---

Key Clinical Trials: What the Numbers Say

The Cochrane Review: 41 RCTs, 4,477 Patients

The most comprehensive systematic review of herbal medicines for functional dyspepsia was conducted under the Cochrane Collaboration and summarized in a 2024 American Family Physician evidence report.

Key findings:

• The review covered 41 randomized controlled trials involving 4,477 adults across 27 different herbal products
• Evidence specifically for peppermint–caraway oil came from three studies involving 305 patients
• All peppermint–caraway studies were placebo-controlled and ran for four weeks
• The treatment group demonstrated improved global dyspepsia symptoms with an absolute risk reduction (ARR) of 28.4%
• The 95% confidence interval for this ARR was 16.1%–43.5%
• The number needed to treat (NNT) was 4, with a 95% CI of 2–6

An NNT of 4 is actually quite clinically meaningful. For comparison, many approved pharmaceutical interventions for functional dyspepsia have NNTs in the range of 5–10 or higher. An NNT of 4 means that for every four patients treated with peppermint–caraway oil instead of placebo, one additional patient experiences significant symptom improvement who would not have improved otherwise.

Critical caveat from the Cochrane review: The evidence was characterized as low-quality RCT evidence. This does not mean the results are wrong — it means the trials had methodological limitations such as small sample sizes, short follow-up periods, potential industry funding bias, and inconsistent outcome measurement tools. Low-quality evidence can still point toward a real effect; it simply means we cannot be as confident as we would be with high-quality trial data.

The 2019 Meta-Analysis: 5 RCTs, 578 Patients

A 2019 meta-analysis pooled five RCTs involving 578 patients and analyzed the effect of peppermint–caraway oil on global functional dyspepsia symptoms.

Results:

• Relative risk: 0.59 (95% CI: 0.49–0.71) for global symptom persistence, meaning patients on peppermint–caraway oil were 41% less likely to still have persistent overall symptoms compared to placebo
• For epigastric pain specifically: RR 1.61 (95% CI: 1.28–2.03), indicating significantly greater pain improvement in the treatment group
• No significant overall difference in adverse events between treatment and placebo groups
• Number needed to harm (NNH): 40 — meaning you would need to treat 40 patients before one additional person experienced an adverse event attributable to the treatment

This NNH of 40, compared to an NNT of 4, represents a favorable risk-benefit ratio on paper, though again the low evidence quality means these figures should be interpreted cautiously.

What These Numbers Mean in Plain Language

Let us translate these statistics into practical terms for someone considering peppermint and indigestion relief:

• Roughly 1 in 4 patients using peppermint–caraway oil for four weeks experienced clinically meaningful improvement in global indigestion symptoms that they would not have experienced on placebo
• Patients were significantly more likely to see improvement in upper-abdominal pain specifically
• The chance of experiencing a side effect from the treatment was low, with only 1 in 40 patients experiencing an adverse event attributable to treatment
• However, all of this is based on trials that researchers consider to be of limited methodological quality

---

The 2025/2026 Menthacarin Phase IV Trial

The most recent and arguably most relevant clinical data comes from a phase IV clinical trial of Menthacarin published online in December 2025 and appearing in print in Wiener Medizinische Wochenschrift in 2026. The trial was authored by Linas et al. and represents a significant step forward in peppermint indigestion research.

Trial Design

• Study type: Phase IV clinical trial (post-market surveillance of an approved preparation)
• Population: 126 patients with unexplained abdominal pain, cramps, or bloating — specifically patients classified under "disorders of gut–brain interaction" (DGBI), which is the updated terminology encompassing functional dyspepsia and related conditions
• Intervention: One Menthacarin capsule twice daily
• Duration: Eight weeks
• Primary outcome: Change in the Nepean Dyspepsia Index (NDI), a validated quality-of-life and symptom severity tool specifically designed for functional dyspepsia

Key Findings

• Patients in the Menthacarin group demonstrated significantly greater improvement in the Nepean Dyspepsia Index compared to the placebo group after the eight-week treatment period
• The trial targeted disorders of gut–brain interaction broadly, which aligns with current gastroenterological thinking that conditions like functional dyspepsia are best understood through the gut–brain axis framework
• The eight-week duration is notably longer than the four-week trials included in the Cochrane review, providing more sustained follow-up data

Why This Trial Matters

Several features make the 2025/2026 Menthacarin trial particularly noteworthy:

1. Phase IV designation: This is not a preliminary exploratory study. Phase IV trials are conducted after a product has received regulatory approval and are designed to gather additional information about safety, efficacy, and optimal use in real-world populations.

1. Validated outcome tool: The use of the Nepean Dyspepsia Index, a well-validated and widely accepted instrument, is a methodological improvement over some earlier trials that used custom or less-standardized symptom scales.

1. DGBI framing: By explicitly studying patients with disorders of gut–brain interaction rather than just "indigestion," this trial engages with current clinical understanding of functional GI disorders.

1. Longer duration: Eight weeks of treatment provides more clinically useful data about sustained benefit than the four-week trials that dominate earlier literature.

Limitation to note: Phase IV trials are often sponsored by the manufacturer of the preparation being studied. This does not automatically invalidate the results, but it is a factor that independent replication studies would need to address.

---

Peppermint Oil Alone vs. Peppermint–Caraway Combination

This is one of the most important and most frequently misunderstood points in the peppermint indigestion literature.

What the NIH Says

The National Center for Complementary and Integrative Health (NCCIH) at the NIH provides the following guidance on peppermint oil and indigestion:

• Some peppermint–caraway combinations may relieve indigestion
• Evidence does not show that peppermint oil alone is effective for indigestion
• Peppermint oil alone may actually worsen indigestion in some people

This last point is critical and deserves elaboration.

Why Peppermint Oil Alone May Worsen Indigestion

Peppermint oil's calcium channel-blocking, spasmolytic effects extend to the lower esophageal sphincter (LES). The LES is the muscular valve that prevents stomach acid from flowing back into the esophagus. When peppermint oil relaxes the LES, it can promote gastroesophageal reflux — the backflow of acid from the stomach into the esophagus.

For patients whose "indigestion" is primarily acid reflux or GERD, peppermint oil — whether as capsules, oil drops, or potentially even peppermint tea indigestion remedies — could theoretically make symptoms worse by weakening the LES.

This is why the clinical trials that show the most consistent benefit use enteric-coated capsules that bypass the stomach and release their contents in the small intestine, rather than formulations that would release peppermint oil in the stomach where it could affect the LES.

The Enteric-Coating Controversy

A 2024 consumer-focused review raised an important limitation regarding industry-funded indigestion studies: the use of enteric-coated capsules that release peppermint oil in the small intestine rather than the stomach means these formulations may not directly address gastric-level symptoms in the same way proponents claim.

The logic: if peppermint oil is released primarily in the small intestine and beyond, its mechanism of action for relieving epigastric (stomach-level) symptoms requires some explanation. Critics argue this design may actually favor tolerability over efficacy at the stomach level.

Proponents counter that functional dyspepsia involves the entire upper GI tract including the proximal small intestine, and that the gut–brain axis effects of peppermint's active compounds may operate more diffusely than a simple stomach-targeting model would suggest.

This debate has not been definitively resolved in the clinical literature and represents an important area for future research.

The Practical Takeaway

If you are considering peppermint benefits indigestion approaches:

• Peppermint–caraway oil combination (e.g., Menthacarin/Enteroplant): Has the most clinical trial support for functional dyspepsia
• Peppermint oil alone: Not well-supported for indigestion specifically; may worsen symptoms in those with acid reflux
• Peppermint tea: Commonly used folk remedy with very limited direct clinical trial evidence for functional dyspepsia specifically (discussed below)

---

Peppermint Tea, Leaves, and Extract: Are They Studied?

One of the most common reader questions is whether clinical trials study peppermint in the forms most people actually use — tea, dried leaves, or liquid extract — or only in highly standardized pharmaceutical-grade capsules.

The honest answer: clinical trials almost exclusively study standardized oil capsule preparations, not tea or leaves.

Peppermint Tea for Indigestion

Peppermint tea indigestion is one of the most searched and most discussed traditional uses of peppermint. However, there is an important distinction between traditional use evidence and randomized controlled trial evidence.

Peppermint tea:

• Contains significantly lower and more variable concentrations of L-menthol than standardized oil capsules
• Has been used traditionally for digestive symptoms across many cultures for centuries
• Has not been the subject of rigorous RCTs specifically for functional dyspepsia
• May have different pharmacokinetics when consumed as a hot beverage vs. absorbed from an oil capsule

A 2025 review of medicinal plants in gastrointestinal supplements acknowledged that peppermint preparations have a traditional-use indication for digestion-related complaints, while simultaneously noting insufficient clinical-trial evidence for some peppermint preparations. Tea-based preparations fall squarely into this "traditional use but insufficient clinical trial evidence" category.

Peppermint Extract for Indigestion

Peppermint extract indigestion products are available as liquid tinctures, concentrated drops, and standardized herbal extracts. These represent a middle ground between tea and pharmaceutical-grade capsules.

The challenge: "peppermint extract" is not a standardized term. Without knowing the extraction method, the menthol concentration, the presence or absence of other compounds, and the delivery mechanism, it is very difficult to extrapolate clinical trial findings from standardized capsules to commercial extract products.

Natural Peppermint for Indigestion

Natural peppermint indigestion approaches — including fresh peppermint leaves, herbal teas, and food-grade culinary use — represent the most traditional forms of peppermint use but the least clinically studied.

For anyone interested in the clinical evidence, it is important to understand that when a study reports that "peppermint improved indigestion symptoms," what was actually tested was almost certainly a standardized, encapsulated oil preparation — not tea, not leaves, and not a typical commercial herbal tincture.

This does not mean tea or extract forms are ineffective. It means they have not been tested in the same rigorous manner and cannot be assumed to produce identical results.

---

Dosage and Formulation Used in Clinical Trials

For those interested in understanding what dose and formulation have actually been used in clinical research — essential information when evaluating any peppermint indigestion supplement — here is what the trials report.

Menthacarin Dose and Composition

The Menthacarin formulation used in the 2025/2026 phase IV trial:

• Dose: One capsule, taken twice daily
• Duration: Eight weeks in the most recent trial; four weeks in earlier RCTs
• Composition: A fixed-ratio combination of peppermint oil and caraway oil
• Delivery: Enteric-coated soft-gel capsules designed to release contents in the small intestine

Typical Trial Parameters Across Earlier Studies

The three peppermint–caraway studies included in the Cochrane review all:

• Used placebo-controlled, parallel-group or crossover designs
• Ran for four weeks
• Used standardized oil combinations in capsule form
• Measured outcomes using global dyspepsia symptom scores

What About Peppermint Oil Alone Studies?

Some earlier trials used peppermint oil alone (not combined with caraway). These trials generally:

• Used enteric-coated capsules containing 0.2–0.4 mL peppermint oil per capsule
• Dosed at one to two capsules, two to three times daily
• Were primarily conducted in IBS populations, not functional dyspepsia specifically

Peppermint Dosage for Indigestion: What the Evidence Supports

Based on the available clinical trial data, the best-supported peppermint dosage indigestion protocol involves:

• A standardized peppermint–caraway oil combination (not peppermint oil alone)
• In enteric-coated capsule form
• At twice-daily dosing
• For a minimum of four to eight weeks

There is no established or evidence-supported dosage for peppermint tea, leaf preparations, or liquid extracts specifically for functional dyspepsia based on current clinical trial data.

---

Side Effects, Safety, and Drug Interactions

Adverse Events in Clinical Trials

The 2019 meta-analysis reported:

• No significant overall difference in adverse event rates between peppermint–caraway oil and placebo
• NNH of 40 — one additional adverse event for every 40 patients treated with peppermint–caraway oil compared to placebo

Commonly reported mild adverse events in peppermint oil trials (across IBS and dyspepsia studies) include:

• Heartburn or acid reflux (particularly with non-enteric-coated formulations)
• Belching with peppermint taste/smell
• Perianal burning (more common in IBS dosing with higher-dose preparations)
• Headache
• Nausea (less common)

Peppermint and Acid Reflux: A Critical Warning

As noted in the NIH guidance, peppermint oil's relaxant effect on the lower esophageal sphincter means it can worsen heartburn and acid reflux. This is perhaps the most important safety consideration for indigestion patients:

• If your indigestion symptoms include frequent heartburn, acid regurgitation, or a burning sensation that travels upward from your stomach, peppermint oil (especially non-enteric-coated forms) may aggravate rather than relieve your symptoms
• Peppermint tea indigestion use specifically carries this risk, as tea is consumed as a warm liquid that would deliver peppermint compounds to the esophagus and stomach before any lower GI delivery

Pregnancy and Breastfeeding

The NIH and most clinical guidance bodies advise caution:

• Pregnancy: The safety of medicinal-dose peppermint oil (as opposed to food-flavoring amounts) during pregnancy has not been established in clinical trials. High doses of menthol are theoretically problematic. Peppermint tea in normal food quantities is generally considered low-risk, but medicinal peppermint oil supplements should be avoided without direct physician guidance.
• Breastfeeding: Similarly, medicinal peppermint oil supplementation during breastfeeding lacks adequate safety data. There are anecdotal reports that peppermint may reduce milk supply, though this is not well-established clinically.

Drug Interactions

Peppermint oil may interact with:

• CYP3A4-metabolized medications: Peppermint oil has some inhibitory effects on cytochrome P450 3A4 enzymes, which are responsible for metabolizing a wide range of medications. In theory, this could increase blood levels of certain drugs. Clinical significance of this interaction at typical supplement doses is uncertain.
• Cyclosporine: There is limited evidence suggesting peppermint oil may affect cyclosporine metabolism.
• Antacids: Antacids that dissolve enteric coatings in the stomach could potentially interfere with the delivery of enteric-coated peppermint oil capsules.
• Iron supplements: Peppermint tea may inhibit iron absorption when consumed at the same time as iron-containing supplements or iron-rich meals.

Always disclose all supplements to your healthcare provider, particularly if you are taking immunosuppressants, anticoagulants, or medications with narrow therapeutic windows.

Who Should Avoid Peppermint Oil Supplements

• People with GERD or frequent acid reflux
• People with hiatal hernia
• People taking cyclosporine or other CYP3A4-sensitive medications
• Pregnant women (without physician guidance)
• People with known allergy to peppermint or menthol
• Children under 12 (peppermint oil applied near the face of young children can cause respiratory distress; oral dosing safety in children is also not well-established)

---

How Strong Is the Evidence Compared to PPIs?

A fair question that many patients and clinicians ask: how does peppermint–caraway oil stack up against standard pharmaceutical treatment for functional dyspepsia?

Evidence Quality Comparison

| Treatment | Evidence Quality | NNT (approx.) | |---|---|---| | Peppermint–caraway oil | Low-quality RCTs | 4 (95% CI: 2–6) | | Proton-pump inhibitors (PPIs) for FD | Moderate-quality RCTs | ~7–10 | | H2-receptor antagonists for FD | Moderate-quality RCTs | ~7–10 | | Prokinetics for FD | Moderate-quality RCTs | ~6–8 | | Tricyclic antidepressants for FD | Moderate-quality RCTs | ~6–7 |

Note: NNT values for PPIs and other pharmaceuticals vary considerably across trials and meta-analyses. These figures are approximate and meant to illustrate relative magnitude only.

The Important Nuance

The NNT of 4 for peppermint–caraway oil sounds favorable compared to pharmaceuticals, but this comparison must be made with extreme care:

1. Evidence quality matters enormously. A low-quality RCT with an NNT of 4 cannot be directly compared to a high-quality RCT with an NNT of 8. The confidence intervals on the peppermint data are wide.

1. Patient populations differ. Not all functional dyspepsia is the same. PPIs work better for patients with predominantly acid-related symptoms; prokinetics work better for patients with motility issues. Peppermint–caraway oil's mechanism suggests it may work best for patients with prominent bloating, cramping, and spasm-related symptoms.

1. No head-to-head trials exist. There are no well-designed trials directly comparing peppermint–caraway oil to PPIs or prokinetics in matched patient populations.

1. Long-term data are lacking. Most peppermint trials run four to eight weeks. Long-term efficacy and safety data (months to years) simply do not exist.

The responsible conclusion: peppermint–caraway oil has a plausible and partially supported role as an adjunct or alternative for select patients with functional dyspepsia — particularly those who have not responded to or cannot tolerate pharmaceutical options — but it should not be positioned as a proven equivalent to established treatments.

---

Is There a 2027 Clinical Trial Coming?

This is the question that drives many searches for "peppermint for indigestion clinical trial 2027."

What the Current Evidence Base Shows

Following a thorough review of available published and pre-registered research, no specific 2027 clinical trial publication on peppermint for indigestion has been identified in the currently available literature. The evidence base as of early 2026 consists primarily of:

• Earlier RCTs from the 1990s and 2000s
• The 2019 meta-analysis
• The 2024 Cochrane-based review in American Family Physician
• The 2025/2026 Menthacarin phase IV trial (the most recent)

What Might Be Expected

While no specific 2027 trial has been announced or identified, the following developments would be logical next steps for the field:

1. Larger, higher-quality RCTs of Menthacarin/Enteroplant: Given the 2025/2026 phase IV data, the natural scientific progression would be a larger confirmatory trial — potentially including 300–500 patients with longer follow-up (12–24 weeks).

1. Head-to-head comparison trials: A well-designed trial comparing peppermint–caraway oil directly to a standard treatment (e.g., a prokinetic or low-dose TCA) in a defined FD subpopulation would significantly advance the field.

1. Mechanistic studies: Trials using biomarkers, gut microbiome analysis, or neuroimaging to understand why and in whom peppermint–caraway oil works would help identify the patient population most likely to benefit.

1. Tea and extract formulation trials: Given the popularity of peppermint tea indigestion and peppermint extract indigestion remedies, there is a clear need — though industry funding interest may be lower — for trials of these more accessible forms.

1. Safety in specific populations: Trials specifically examining safety and efficacy in elderly patients, patients with comorbid GERD, and patients on polypharmacy would help clinicians make evidence-based recommendations.

How to Find 2027 Trial Updates

If you want to track whether a 2027 peppermint indigestion trial is registered or published:

• ClinicalTrials.gov (clinicaltrials.gov): Search "peppermint dyspepsia" or "Menthacarin" to find registered trials
• EU Clinical Trials Register (clinicaltrialsregister.eu): For European trials
• PubMed (pubmed.ncbi.nlm.nih.gov): For published trial results; search "peppermint functional dyspepsia 2027"
• Cochrane Library (cochranelibrary.com): For updated systematic reviews

---

Frequently Asked Questions

Does peppermint help indigestion, or only irritable bowel syndrome?

Peppermint — specifically peppermint oil in enteric-coated capsules — has more established clinical evidence for irritable bowel syndrome (IBS) than for indigestion/functional dyspepsia. However, the peppermint–caraway oil combination (Menthacarin) has shown statistically significant benefits for functional dyspepsia in RCTs. Peppermint oil alone for indigestion is not well-supported by the current evidence, and the NIH specifically notes it may not be effective for indigestion when used alone.

Is peppermint oil alone effective, or is the peppermint–caraway combination better studied?

The peppermint–caraway combination is significantly better studied for functional dyspepsia. Peppermint oil alone lacks robust evidence for indigestion and may worsen symptoms by relaxing the lower esophageal sphincter, potentially worsening acid reflux.

What clinical trials support peppermint for functional dyspepsia?

The most important trials are: (1) three RCTs involving 305 patients analyzed in the Cochrane review, showing a 28.4% absolute risk reduction; (2) a 2019 meta-analysis of five RCTs with 578 patients showing RR 0.59 for symptom persistence; and (3) the 2025/2026 Menthacarin phase IV trial involving 126 patients over eight weeks showing significantly improved Nepean Dyspepsia Index scores.

How quickly does peppermint–caraway oil relieve symptoms?

Clinical trials have not consistently reported time-to-response data with precision. Most trials measured outcomes at four weeks. The 2025/2026 trial ran for eight weeks, with results reported at trial end. Anecdotally and based on mechanism, some patients may notice effects within days, but clinical studies do not support claiming rapid onset.

What dose and formulation were used in clinical trials?

The best-studied formulation is Menthacarin — a fixed-ratio peppermint–caraway oil combination in enteric-coated capsules, dosed at one capsule twice daily for four to eight weeks.

Are enteric-coated peppermint capsules appropriate for indigestion?

This is debated. Enteric coating ensures the oil is released in the small intestine rather than the stomach, which may be appropriate for IBS (targeting the lower GI tract) but raises questions about efficacy for gastric-level indigestion symptoms. The 2024 consumer review highlighted this limitation. The clinical trial data still shows benefit with enteric-coated preparations for functional dyspepsia, but the exact mechanism remains under discussion.

Can peppermint worsen heartburn or acid reflux?

Yes. This is well-documented. Peppermint oil relaxes the lower esophageal sphincter, which can allow stomach acid to reflux into the esophagus. Patients with GERD, frequent heartburn, or hiatal hernia should use caution or avoid peppermint oil supplements entirely. Enteric-coated capsules reduce but may not eliminate this risk.

What side effects were reported in peppermint clinical trials?

Mild side effects include heartburn, peppermint-flavored belching, perianal burning (at higher doses), headache, and nausea. The 2019 meta-analysis found no statistically significant difference in overall adverse events between peppermint–caraway oil and placebo, with an NNH of 40.

Is peppermint safe during pregnancy or while taking other medicines?

Not established as safe during pregnancy at medicinal supplement doses. Peppermint tea in normal beverage quantities carries minimal documented risk, but medicinal peppermint oil supplements should be avoided without direct medical supervision during pregnancy. Regarding drug interactions, peppermint oil may affect CYP3A4 enzyme activity, potentially altering metabolism of certain medications. Always consult your healthcare provider.

How strong is the evidence compared with proton-pump inhibitors or standard dyspepsia treatments?

The NNT for peppermint–caraway oil (approximately 4) is numerically favorable compared to PPIs for functional dyspepsia (NNT approximately 7–10), but the evidence quality for peppermint is characterized as low, whereas PPI evidence is generally of moderate quality. No head-to-head comparison trials exist. Peppermint–caraway oil may be a reasonable option for patients with bloating-predominant symptoms who cannot tolerate or have not responded to pharmaceutical options, but it cannot be considered a proven equivalent.

Are there any peppermint-for-indigestion trials scheduled or expected in 2027?

No specific 2027 trial has been identified in the current literature or clinical trial registries as of this writing. The most recent published data is from the 2025/2026 Menthacarin phase IV trial. Checking ClinicalTrials.gov and PubMed regularly is the best way to identify new trials as they are registered or published.

Do current studies evaluate peppermint tea, peppermint leaves, or only standardized oil capsules?

Current clinical studies almost exclusively evaluate standardized oil capsule preparations. Peppermint tea and leaf preparations have not been the subject of rigorous RCTs for functional dyspepsia. The traditional-use evidence for these forms is noted in herbal medicine reviews, but they lack the clinical trial evidence base that standardized oil combinations possess.

---

Bottom Line

Here is what the complete body of evidence on peppermint for indigestion actually tells us as we look toward 2027:

What Is Well-Supported

✅ Peppermint–caraway oil combinations (particularly Menthacarin/Enteroplant) have demonstrated statistically significant improvement in functional dyspepsia symptoms in multiple RCTs, with an NNT of approximately 4 in pooled analysis

✅ The most recent evidence comes from the 2025/2026 Menthacarin phase IV trial (126 patients, 8 weeks), showing significantly improved Nepean Dyspepsia Index scores versus placebo

✅ The adverse event profile is favorable, with an NNH of 40 in pooled analysis and no significant overall difference in adverse events in most trials

✅ Peppermint and indigestion relief via the peppermint–caraway combination is supported by the Cochrane review as potentially beneficial, though evidence quality remains low

What Is Not Well-Supported

❌ Peppermint oil alone is not supported for indigestion and may worsen acid reflux symptoms

❌ Peppermint tea indigestion and peppermint leaf preparations have not been rigorously studied in RCTs for functional dyspepsia

❌ Long-term safety and efficacy beyond eight weeks has not been established in clinical trials

❌ No 2027 clinical trial has yet been identified or published; anyone hoping for definitive 2027 trial data should monitor ClinicalTrials.gov and PubMed

The Honest Clinical Picture

The best peppermint for indigestion approach — based on current evidence — is a standardized peppermint–caraway oil combination in enteric-coated capsule form, dosed twice daily for at least four weeks, used by patients with bloating, cramping, and functional dyspepsia symptoms who do not have predominant acid reflux or GERD.

The evidence is promising enough to justify use as a complementary option. It is not yet strong enough to position peppermint as a first-line, proven treatment equivalent to established pharmaceutical options. The field needs larger, higher-quality, independently funded RCTs — ideally with longer follow-up, head-to-head comparisons with standard care, and mechanistic substudies.

If you are considering a peppermint indigestion supplement, discuss it with your gastroenterologist or primary care physician, disclose all other medications, rule out underlying structural causes of your symptoms, and set realistic expectations based on the current state of evidence.

---

Sources referenced in this article include the American Family Physician 2024 Cochrane evidence summary on herbal medicines for dyspepsia, the National Center for Complementary and Integrative Health (NCCIH/NIH) guidance on peppermint oil, and the 2025/2026 Linas et al. Menthacarin phase IV trial published in Wiener Medizinische Wochenschrift. Statistical figures are reported as published in the cited literature.